Investigational drug · Phase 2
SGX-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Granulomatous Disease (CGD).
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "SGX-001"
First trial start
2026
Aug 18, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SGX-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Granulomatous Disease (CGD)
Largest trials
Live from ClinicalTrials.gov: studies naming "SGX-001" as an intervention, largest first.
- Open-label Gene Therapy Study in p47-CGDRecruiting
Somagenetix AGIndustry
NCT07826767 · 5 participants (planned) · Start Aug 18, 2026 · Primary completion Jul 2028
Drug: SGX-001 · For: Chronic Granulomatous Disease (CGD)
Sites: Ulm, Germany; Barcelona, Spain; Zurich, Switzerland
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.